CapEval Pharma

Executive Summary

CapEval Pharma is a French pharmaceutical consultancy established in 2010, specializing in non-clinical drug development services. With over 30 years of collective industry experience, the firm supports biotech and pharmaceutical clients in due diligence, licensing, fundraising, and outsourcing management. Its core focus lies in guiding new chemical and biological entities from discovery through clinical development. As a privately held, pre-clinical stage company, CapEval Pharma operates without proprietary drug pipelines, instead leveraging its expertise to de-risk and accelerate client programs. The consultancy's Paris base positions it within Europe's vibrant biopharma ecosystem, enabling it to serve a global clientele. While CapEval Pharma's revenue model is service-based, its success is tied to client milestones and repeat business. The company's profile remains low profile, with limited public disclosures, making it a niche player in the CRO-adjacent consulting space. Given the steady demand for specialized regulatory and development support, CapEval Pharma is well-positioned for sustained, albeit modest, growth.

Upcoming Catalysts (preview)

• Q4 2026New strategic partnership with a top-20 pharma company60% success
• Q1 2027Launch of a digital consulting platform for remote drug development40% success
• Q3 2026Expansion into biologics and cell/gene therapy consulting services50% success